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ABSTRACT

Holloway, Connor J. M.S., Purdue University, May 2015. Evaluating Breast Cancer Stem
Cell Response to Antiangiogenic Therapy. Major Professor: Keith Stantz.

Angiogenic inhibitors function by blocking tumor cell signals used to recruit host
tissue vasculature to the tumor site, thereby depriving the cancer of the nutriment needed
for further expansion. The development and implementation of angiogenic inhibitors in
conjunction with standard chemotherapy agents has increased progression-free survival
but not overall patient survival. It is hypothesized that chronic exposure to large doses of
AAT drugs worsens hypoxic conditions within the tumor mass, selectively stimulating
aggressive cancer stem cell populations to grow and proliferate.
In this study, the expression of the CSC biomarkers ALDH1, DLL1, and EpCAM
were evaluated in breast cancer tumors grown in mouse models for varying doses of
angiogenic inhibitor DC101 using a threshold analysis technique developed in-house.
SUM149 triple-negative breast cancer cells were grown in athymic nude mice and
administered either 10mg/kg, 40mg/kg, or 120mg/kg DC101, corresponding to “Low
Dose”, “Medium Dose”, and “High Dose”, respectively. Following a period of several
days, the tumors were harvested, sectioned into slices at specific depths, and stained for
one of each biomarker. Stained sections were scanned into a computer, where images
were subjected to a series of coded protocols written in-house for Matlab or IDL. Images
were segmented to remove non-target background pixels and co-registered to a series of
static images to allow for comparative analysis. Biomarker-specific thresholds were
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applied to separate biomarker-positive image pixels from those pixels deficient in the
biomarker stain. Pixel values were counted for both the control tumor slides and those
having received DC101 exposure. Values were compared to evaluate changes in
biomarker expression with variations in dose concentration. Pixel values were also
compared between corresponding slices stained for different biomarkers in order to
determine the prevalence of spatially-overlapping regions.
Experimental results demonstrate a significant (p < 0.05) decrease in ALDH1 and
DLL1 biomarker expression for the MD groups compared to controls, and elevated
expression in the HD group compared to the LD and MD groups for the same biomarkers.
Changes were most dramatic in the expression of the DLL1 biomarker. EpCAM
expression did not vary significantly (p < 0.05) with dose. Variations in overlap between
ALDH1 and EpCAM suggest that expression of the two biomarkers may be linked, while
DLL1 overlap data suggests that DLL1 expression is independent of ALDH1 and
EpCAM. Through a combination of perfusion imaging and biomarker expression, our
data suggest that “medium dose” concentrations of 40mg/kg of DC101 can affect
normalization of tumor vasculature within our mouse models, thereby alleviating hypoxia
within the tumor microenvironment. While our ALDH1 quantification results provide
some validation for our technique, future goals should focus on further validation through
additional quantification of known biomarkers, the incorporation of PCA, and the use of
the variance factor in the co-registration script to assess accuracy of the co-registration
process.
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CHAPTER 1. INTRODUCTION

1.1

Antiangiogenic Therapy

Research into the treatment of cancers has yielded a multitude of different
approaches and techniques. While a growing body of attention has focused on genomics
for a more personalized experience, existing treatments most commonly include radiation
exposure in conjunction with a carefully-planned regimen of cytotoxic chemical agents.
Among those drugs considered for cancer treatment are a class referred to as angiogenic
inhibitors, which attempt to stem tumor growth through the inhibition of blood vessel
formation. Despite setbacks from clinical trials, the potential of angiogenic inhibitors
remains a subject of ongoing study.
Angiogenesis is characterized in normal tissue by the formation of capillary micro
vessels in response to migrating and proliferating endothelial cells. Regulated by a host of
inhibitors and growth factors1, angiogenesis is a critical component in wound repair,
tissue development, and reproduction. While this process typically transpires over a selflimited period of weeks or months, pathology-linked angiogenesis can persist chronically
for

years. Such angiogenesis-dependent

diseases

include

age-related

macular

degeneration, rheumatoid arthritis, atherosclerosis, and cancer; angiogenesis is critical to
fueling the prolonged growth of neoplasms and their associated metastases.
Originally conceptualized in the late 1970s1,2, antiangiogenic therapy was first
theorized following the successful development of angiogenesis bioassays. In contrast to
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existing chemotherapy agents that target specific components of mitotic division, the
theory behind AAT centers on the notion of cellular starvation: Tumors must sustain their
constant expansion through the recruitment of new blood vessels, diverting oxygen and
nutriment into their growing mass. By blocking blood vessel recruitment, it was theorized
that sustained cell division would no longer be possible as supplies of glucose and
oxygen were gradually exhausted. This alternative approach offered the potential for
greater sparing of healthy tissue: While cell division-targeting drugs would exhibit
cytotoxic effects on all dividing cells in the body, including normal cells, AAT drugs
would only block the formation of new blood vessels, leaving existing vasculature intact.
Research into this technique has led to the development of a variety of functional
AAT drugs, the earliest of which began clinical trials in the mid-1990s1. Bevacizumab, a
monoclonal antibody approved in 2004 for the treatment of colorectal cancer by the US
Food and Drug Administration, was the first of these new drugs developed solely as an
angiogenic inhibitor and is one of the better-studied of the emerging AAT agents.
Marketed under the trade name Avastin, the drug disrupts the activity of vascular
endothelial growth factor A (VEGF-A), one of the leading promoters of angiogenesis1,3,4.
Similar drugs such as the kinase inhibitor sunitinib and monoclonal antibody DC101
were developed to target VEGFR kinase activity5 and antigen binding5,6, respectively.
After years of studies accumulated, a common trend in AAT treatment of
cancerous lesions manifested: While angiogenic inhibitors may provide positive clinical
benefits against established tumor cell populations, they are not increasing overall patient
survival. Bevacizumab was shown to confer no significant benefit to overall patient
survival in cases of metastatic breast cancer4, and both sunitinib and DC101 were shown
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to increase the rate of spontaneous metastasis in laboratory mice5-7 as well as increase
long-term tumor invasiveness6,7. These results suggest a relationship exists between AAT
drugs and metastatic growth.
One hypothesis purports that hypoxic conditions, which have already been
implicated in decreased treatment effectiveness due to the decreased availability of
reactive oxygen species8, are being worsened by exposure to angiogenic inhibitors. The
tortuous and abnormal development of vasculature within cancerous lesions creates
natural regions of chronic hypoxia, which are further intensified by rapid degeneration of
tumor vasculature within the tumor mass. Such developments could inadvertently select
for those cells which can survive under nutrient-starved conditions and therefore promote
the growth of more aggressive cancer cells9,10. Additionally, extrapolating from gene
regulation mechanisms identified in human embryogenesis, it is theorized that hypoxia
may play a role in the activation of certain growth-specific gene expression pathways in
cancer cells9.
To address these circumstances, some researchers have pursued alternative AAT
techniques: Instead of ablating blood vessel recruitment with high doses of angiogenic
inhibitors, lower doses can be used to normalize tumor vasculature. Vasculature
normalization can have the dual effect of increasing oxygen perfusion to the tumor mass,
thereby alleviating hypoxic conditions and the various associated complications, and
better allowing chemotherapy agents to access cancer cells within the tumor interior9,10.
Identifying dose concentrations that achieve the desired normalization effect is the
subject of ongoing research.
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1.2.1

Cancer Stem Cell Hypothesis

Stem cells are undifferentiated cells within a tissue that are functionally capable of
indefinite division and self-renewal, thereby providing a regenerative pool for continuous
tissue replenishment. Homeostatic regulations for cells within a tissue are maintained at
the stem cell level11. Following division, one of the two resulting cells will retain its
undifferentiated, stem-like properties, while the other cell will have begun to differentiate
into a progenitor cell. Unlike its predecessor, a progenitor cell loses the capacity to
sustain indefinite division and will begin to express the properties and characteristics of
the more mature, fully differentiated cells of the surrounding tissue type.
With regards to the multi-step model of carcinogenesis, wherein normal cells may
become cancerous after sustaining several uncorrected mutations over multiple
generations, it is unsurprising that loss of homeostatic regulation can cause normal adult
stem cells to divide uncontrollably. These cancer stem cells, stem-like cells whose
homeostatic mechanisms have been altered or subverted, can arise from either mutated
adult stem cells or progenitor cells that have dedifferentiated back into stem cells10-13.
The CSC hypothesis maintains that these stem-like cancer cells are the basis of selfpropagating tumors: Small subpopulations of CSCs maintain growth of the larger tumor,
with daughter cells differentiating into mature cells of the CSC tissue type with finite
growth capacities11.
Experimental evidence strongly supports the existence of CSCs10-13. Additional
evidence suggests that hypoxic tissue conditions induce expression of certain
transcription factors which contribute to tumor progression9 and may cause differentiated
tumor cells to revert back into undifferentiated CSCs9,13. The impact of tissue hypoxia on
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CSC populations makes its alleviation a high priority for the improvement of cancer
therapy outcomes.
1.2.2

CSC Biomarkers

Studies of tumor histology have provided a means of visualizing CSC populations.
The effect of a drug, for example, on CSC populations can be monitored through
quantifying the cells within a tumor volume that express specific CSC biomarkers.
Multiple CSC biomarkers have been identified in previous experiments, including
combinations of clusters of differentiation proteins11,14, cell surface adhesion molecules15,
and cytosolic enzymes12,16.
One such biomarker is ALDH1, a detoxifying enzyme that catalyzes the oxidation
of aldehyde groups into carboxylic acids. Its ability to metabolize retinol into retinoic
acid is under investigation for its role in stem cell differentiation12,16. Found
predominantly in liver cells due to its metabolic significance, overexpression has been
associated with negative clinical prognosis for malignant human mammary stem cells12,16.
ALDH1 expression on the exterior of the plasma membrane has been demonstrated in
both CSCs and progenitor cells, while internal ALDH expression is strictly associated
with the undifferentiated stem cells16. Antibody staining techniques may be utilized to
identify ALDH expression on cell surfaces, while the ALDEFLUOR assay has been used
to identify cells with cytosolic ALDH expression.
EpCAM is a transmembrane glycoprotein found frequently on the basolateral
surfaces of various epithelial cells, enabling cell-cell adhesion through calciumindependent pathways15,17. Increased EpCAM activity correlates inversely with standard
cadherin-mediated adhesion, which has the effect of deregulating epithelial cell growth
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and differentiation and increasing epithelial cell proliferation17. EpCAM is being
investigated as a potential target for cancer therapy due to its documented overexpression
in a variety of carcinomas, including those originating in the pancreas, breast, prostate,
and colon15,17.
DLL1 is a delta ligand homolog in humans that participates in multiple Notch
signaling pathways: Ligands are passed from a signaling cell to the Notch cell surface
domain, which initiates a series of cleavage events that in turn release transcription
factors into the intracellular space. It is perhaps best known for its role in directing
progenitor cell differentiation, promoting characteristics of T-cell precursors while
blocking progression into B-cells19. Additionally, Notch signaling via DLL1 regulates
stem cell renewal and differentiation in the lumen of normal breast tissue, a property that
has been implicated in the initiation and progression of cancer cells13,18.
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CHAPTER 2. METHODOLOGY

2.1

Specific Aims

One goal of this study is to identify a dose window in which biomarker-expressing
cancer cell populations are reduced, which will provide insight into the optimum dose
concentration for tumor vasculature normalization. Another goal is to simultaneously
evaluate the validity of our simple threshold technique and the biomarkers it uses for
CSC population monitoring. To that end, expression of ALDH1, EpCAM, and DLL1 will
be assessed in breast cancer tumors. The three specific aims of the study are as follows:
1) Demonstrate relative variations in biomarker expression between biomarkers in
breast tumor tissue
2) Demonstrate changes in biomarker expression with variations in administered
angiogenic inhibitor
3) Observe changes in overlapping regions of biomarker expression

Firstly, it is imperative to quantify a baseline of existing biomarker expression in
tumor tissue, as changes to this baseline will demonstrate the effects of the angiogenic
inhibitor on CSC populations. To achieve this objective, breast cancer tumors grown in
live mouse models will be sampled, stained via immunohistochemistry techniques, and
biomarker expression will be quantified through image processing via Matlab and IDL
codes developed in-house.

8
Once a baseline has been established, assessments can be made regarding the
effect that different concentrations (low dose, medium dose, and high dose) of angiogenic
inhibitor have on the target biomarkers. After completing a specific drug administration
protocol, breast cancer tumors grown in athymic nude mice will be sampled, stained via
IHC, and biomarker expression will be quantified for each drug concentration through
image processing via Matlab and IDL codes developed in-house. Values obtained from
this analysis will be compared to those obtained for aim 1 to determine the effect of the
inhibitor on biomarker expression.
Finally, overlapping regions that register as positive for different biomarker stains
sections will be quantified in order to assess the significance of biomarker spatial
distributions. Using slides processed during the first two aims, different stained sections
corresponding to similar cut depths will be analyzed simultaneously using IDL code
developed in-house.
Validation of the proposed threshold-based technique will be accomplished by
comparing ALDH1 expression results with existing quantification data acquired in a
separate experiment12, which used a fluorescence-activated cell sorting technique for the
same tissue type. The feasibility of using EpCAM and DLL1 as biomarkers for CSC
populations will be determined based on their expression patterns with respect to changes
in DC101 dose and by comparison with expression of ALDH1, a well-established CSC
biomarker.
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2.2

Cell Growth and Image Acquisition

Thirteen athymic nude mice, separated into roughly equal groups (group 1
contained four mice, while groups 2, 3, and 4 contained three mice each), were imaged
with photoacoustic computed tomography (PCT-S) and dynamic contrast computed
tomography (DCE-CT) to determine SaO2 levels and fractional vascular volume,
respectively. All mice were given intraperitoneal injections of SUM149 triple-negative
inflammatory breast cancer cells and allowed time for tumors to grow to an average
8.5mm- to 9.0mm-diameter size. Mice groups 2, 3, and 4 were then administered
10mg/kg (corresponding to “low dose”), 40mg/kg (corresponding to “medium dose”),
and 120 mg/kg (corresponding to “high dose”) respectively, of the DC101 monoclonal
antibody specific to VEGFR2. DC101 was administered three times daily, at three-day
intervals, over a seven-day period via intraperitoneal injection.
One day following final dose administration, mice were again imaged using PCT-S
and DCE-CT techniques to assess perfusion and fractional vascular volume, respectively.
All mice were then sacked and tumors were excised by the pathology department at
Indiana University Medical Center (Indianapolis, IN). Tumors were sectioned in half and
soaked in 10% formalin buffer solution for 24-48 hours, after which they were transferred
to 70% ethyl alcohol solution until they could be paraffin fixed. Initial cuts were taken at
1.0mm increments from the original section (read: center of original tumor mass), with
additional slices taken at 4-6μm from each cut site. Slices corresponding to a specific cut
depth (1.0mm, 2.0mm, or 3.0mm) were mounted on glass slides and stained: Each
individual slice received either Hematoxylin with Eosin counterstain, or biomarkerspecific antibodies with Diaminobenzidine primary stain and Hematoxylin counterstain.
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Histology slides were imaged via Olympus BX41 Light Microscope using Cellcens
Dimensions software and DP72 camera (Olympus, PA). Images were taken using a
manual 57μs exposure time and saved in JPEG format at maximum quality settings.
A

C

B

Figure 2.1: Tumor sections were treated separately with antibodies for ALDH1 (A),
EpCAM (B), and DLL1 (C) before being stained with DAB stain and Hematoxylin
counterstain. Section slides were then scanned into the computer for processing.

2.3

Image Segmentation

Segmentation script was devised in-house (Mario Dzemidzic, IUPUI) in MatLab
and applied to each image. The segmentation code separates tissue from the image
background in accordance with the process described in Brett Shoelson’s Webinar
(Medical Imaging Workflows with Matlab; http://www.mathworks.com/videos/medicalimaging-workflows-with-matlab-81850.html).

JPEG color images are converted to

grayscale and binarized using the automated Otsu’s method. The resulting image masks
are then cleared of non-tissue objects near the image borders. When appropriate, manual
thresholds can be applied on a slice-by-slice basis using custom Matlab scripts. The
resulting output images include the grayscale mask, individual color masks, and the
original true color image with segmentation corrections applied.
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B

A

Figure 2.2: Segmentation script in Matlab uses the automated
Otsu’s method to remove background pixels and all non-target
tissue impinging from outside the image boundaries. (A) denotes
the original image, (B) denotes the image after segmentation.
2.4

Image Co-registration

Co-registration script was devised in-house (Mario Dzemidzic, IUPUI) in MatLab
and applied to those color images that had undergone segmentation. Tissue sections
stained with H&E are selected as “fixed”, or stationary, images to which other “moving”
stained sections can be co-registered. Moving images are initially resampled using spline
interpolation and are either zero-padded or edge-trimmed to match the size and pixel
dimensions of their corresponding fixed image. The algorithm determined any necessary
geometric transformations using the imgregtform function in the Image Processing
Toolkit. Optimization was achieved by accounting for sectioning-related tissue
distortions and minor spatial offsets during the staining process. Co-registration was
performed in three distinct iterations: The first two iterations used similarity translations
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(rotational, translational, and scaling) to match the moving image to the fixed image as
best possible, while the third iteration accounted for both similarity and shearing which
may have occurred during tissue handling. Output JPEG images were saved for each
iteration of shifts to the moving image, with those resulting from the final iteration being
used for subsequent steps.
A

B

C

Figure 2.3: Segmented images (A) are translated, rotated, and resized (B) to co-register to
the dimensions of a fixed H&E slide (C) for a given slice depth.

2.5

Image Thresholds

Code to apply thresholds was developed in-house in IDL and applied to all coregistered images. Thresholds were determined individually for each biomarker stain
through qualitative, visual assessment of the segmented images based on the quantity of
counterstain present in a given pixel; thresholds were designed to exclude pixels with
high blue-channels values, corresponding to high and low concentrations of counterstain
and primary stain, respectively. Sets of tissue sections stained for the same biomarker
then had thresholds applied to them such that pixels containing sufficient counterstain to
constitute “negative” biomarker expression were assigned one value, “positive” pixels
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were assigned a different value, and those pixels rendered as “background” by the
segmentation code were assigned a zero value. To compensate for potential errors in the
co-registration process, images were binned at 2x (2x2 pixel squares per bin). Both
binned and non-binned images were exported and saved in JPEG format.
A

B

C

Figure 2.4: Co-registered images (A) are exposed to a manually-set threshold value,
specific to each biomarker, which separates pixels into “positive” and “negative”
values (B). Results are binned (C) and exported separately from non-binned images.

2.6

Image Quantification

Quantification code was developed in-house using IDL and was applied to JPEG
images after thresholds. For each run of the script, two images of corresponding section
depth and different biomarker stain were read into the program and the number of
“positive” and “negative” pixel values were counted for each image. The two images
were then compared against each other, and overlapping values (positive/positive,
positive/negative, negative/positive, and negative/negative) were counted. The results
were displayed along with the image dimensions in the IDL interface.
Biomarker presence was noted as a percentage of the total tissue slice volume. Slice
values for a given tumor were averaged to estimate the average percentage of the total
tumor volume. The resulting values for each tumor were averaged together to acquire an
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aggregated average of the percentage of biomarker per total tumor volume. For specific
aim 1, the average percentages of total tumor volume for each control cohort were
compared. For specific aim 2, control results were compared to averages resulting as a
function of DC101 dose for each biomarker. For specific aim 3, average values for
regions of overlap between biomarkers were compared as a function of DC101 dose. All
statistical significance was determined using p-values derived from two-tailed T tests
assuming unequal variance.
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CHAPTER 3. RESULTS

3.1

Specific Aim 1

Threshold values used to separate pixels for positive and negative biomarker
expression for ALDH1, EpCAM, and DLL1 were found to be 155, 50, and 70,
respectively. Results for average biomarker percentage by total tissue volume are
displayed in Table 3.1 and Figure 3.1. Average biomarker expression per control tumor
was found to be 3.61%±1.39, 3.54%±3.80, and 18.39%±13.70 for ALDH1, EpCAM, and
DLL1, respectively. All values are represented as percentages of the total tumor tissue
volume.

Biomarker Expression for Control Tumors
Average % of Total Tissue Volume

35
30
25
20
15
10
5
0
ALDH1

EpCAM

DLL1

Figure 3.1: Biomarker quantification for control tumors,
expressed as a percent of total tumor tissue volume
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Table 3.1: Average biomarker expression per tumor,
expressed as a percentage of total tumor volume
ALDH1 (%) EpCAM (%) DLL1 (%)
M1
4.8071
9.2065
12.6372
M2
2.1570
1.3642
1.7834
M3
2.6970
1.3688
31.0833
M4
4.7979
2.2319
28.0369
Average
3.6148
3.5428
18.3852
Std Dev
1.3891
3.7977
13.6999

3.2

Specific Aim 2

Results for ALDH1 dose response to DC101 are displayed in Figure 3.2. Average
ALDH1 expression for LD (10mg/kg), MD (40mg/kg), and HD (120mg/kg) was found to
be 1.81%±0.84, 1.05%±0.10, and 1.90%±0.48, respectively. Statistically significant (p <
0.05) differences were most closely observed between ALDH1 expression in the control
tumors and the MD tumors, with non-trivial (p < 0.10) changes observed between control
and LD tumors, control and HD tumors, and MD and HD tumors.
Results for EpCAM dose response to DC101 are displayed in Figure 3.3. Average
EpCAM expression for LD, MD, and HD tumors was found to be 2.19%±0.85,
1.08%±0.58, and 1.83%±0.22, respectively. No statistically significant differences were
observed between any of the different tumor groups.
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Dose Response of ALDH1 to DC101
Average % of Total Tissue Volume
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Figure 3.2: ALDH1 dose response to DC101, expressed in terms of average % of total
tumor tissue volume

Dose Response of EpCAM to DC101
Average % of Total Tissue Volume
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Figure 3.3: EpCAM dose response to DC101, expressed in terms of
average % of total tumor tissue volume

Results for DLL1 dose response to DC101 are displayed in Figure 3.4. Average
Figure 3.2.2: EpCAM dose response to DC101 for non-binned and
DLL1 expression for LD, MD, and HD tumors was found to be 2.44%±0.61,
binned images
2.74%±0.1.54, and 14.10%±3.58, respectively. Statistically significant (p < 0.05)
differences were observed between the LD and HD tumors and MD and HD tumors.
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Dose Response of DLL1 to DC101
Average % of Total Tissue Volume
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Figure 3.4: DLL1 dose response to DC101, expressed in terms of the
average % of total tumor tissue volume

3.3

Specific Aim 3

Results for the overlapping ALDH1/EpCAM expression response to DC101 dose
from both non-binned and binned images are displayed in Figure 3.5 and Tables 3.2 and
3.3. Average overlap for controls, LD, MD, and HD tumor groups was observed to be
0.112%±0.070, 0.049%±0.019, 0.042%±0.005, and 0.092%±0.008, respectively, for nonbinned images. For binned images, average overlap for controls, LD, MD, and HD tumor
groups was observed to be 0.065%±0.073, 0.022%±0.012, 0.012%±0.001, and
0.030%±0.004, respectively. Statistically significant (p < 0.05) differences were observed
between LD and HD tumor groups both non-binned images and MD and HD tumor
groups for both binned and non-binned images. Statistically significant (p < 0.05)
differences were also observed between binned and non-binned images for both the MD
and HD tumor groups.
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Average % of Total Tissue Volume

Dose Response of ALDH1/EpCAM Overlap to
DC101, Non-Binned and 2x Binning
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Figure 3.5: ALDH1/EpCAM dose response to DC101 for non-binned and
binned images
Table 3.2: Average ALDH1/EpCAM expression for non-binned
and binned image results, expressed as a percentage of the total
tumor volume. P-values are included for comparison between
non-binned and binned image results
Average Dose Comparison - Non-Binned vs Binned
Control (%) 10mg/kg (%) 40mg/kg (%) 120mg/kg (%)
No Bins
0.1119
0.0494
0.0417
0.0917
Binned
0.0648
0.0221
0.0124
0.0304
p
0.3874
0.1157
0.0072
0.0011

Table 3.3: Associated p-values of ALDH1/EpCAM dose
response relationships for non-binned and binned images
results

Dose Response Comparison - Non-Binned and Binned
Ctrl-LD Ctrl-MD Ctrl-HD LD-MD LD-HD MD-HD
No Bins 0.1720 0.1720 0.6066 0.5621 0.0454 0.0014
Binned 0.3280 0.3280 0.4146 0.2884 0.3517 0.0125
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ALDH1/EpCAM overlap expressed in terms of total ALDH1-positive and
EpCAM-positive expression regions are displayed in Figure 3.6 and 3.7. Of the total
ALDH1-positive populations identified, regions of overlap with EpCAM-positive
populations

accounted

for

3.313%±1.378,

3.503%±2.408,

4.260%±0.753,

and

5.121%±0.590 for controls, LD, MD, and HD tumor groups, respectively, in non-binned
images; for binned images, overlap accounted for 2.100%±1.626, 1.961%±1.028,
1.981%±0.436, and 2.649%±0.426 for controls, LD, MD, and HD tumor groups,
respectively. For EpCAM-positive regions, overlap with ALDH1 accounted for
5.714%±2.111, 3.618%±1.978, 4.828%±2.225, and 6.890%±2.381 for controls, LD, MD,
and HD tumor groups, respectively, in non-binned images; in binned images, overlap
accounted for 3.658%±1.743, 2.245%±0.994, 2.660%±1.538, and 4.164%±1.832 for
controls, LD, MD, and HD tumor groups, respectively. No statistical significance (p <
0.05) was observed between any of the ALDH1 or EpCAM results.

% ALDH1 in ALDH1/EpCAM Overlap, Non-Binned
and 2x Binning
7.0000
6.0000

% ALDH1

5.0000
4.0000

No Bins

3.0000

Binned

2.0000
1.0000
0.0000
Control

10mg/kg

40mg/kg

120mg/kg

Figure 3.6: ALDH1/EpCAM dose response to DC101, expressed in
terms of % of total ALDH1-positive regions
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% EpCAM in ALDH1/EpCAM Overlap to DC101,
Non-Binned and 2x Binning
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Figure 3.7: ALDH1/EpCAM dose response to DC101, expressed in
terms of % of total EpCAM-positive regions
Results for the overlapping ALDH1/DLL1 expression response to DC101 dose
from both non-binned and binned images are displayed in Figure 3.8 and Tables 3.4 and
3.5. Average overlap for controls, LD, MD, and HD tumor groups was determined as
being 0.775%±0.726, 0.069%±0.005, 0.050%±0.019, and 0.220%±0.057, respectively, in
the non-binned image sets. For the binned images, average overlap was found to be
0.642%±0.658, 0.032%±0.013, 0.019%±0.009, and 0.115%±0.034 for the control, LD,
MD and HD tumor groups, respectively. Statistically significant (p < 0.05) differences
were observed between LD and HD tumor groups and MD and HD tumor groups for both
non-binned and binned images. Additionally, statistically significant (p < 0.05)
differences were observed between non-binned and binned image sets for the LD tumor
groups, with non-trivial (p < 0.10) differences observed between non-binned and binned
images for the MD and HD tumor groups.
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Average % of Total Tissue Volume

Dose Response of ALDH1/DLL1 Overlap to
DC101, Non-Binned vs 2x Binning
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Figure 3.8: ALDH1/DLL1 dose response to DC101 for non-binned and
binned images
Table 3.4: Average ALDH1/DLL1 expression for nonbinned and binned image results, expressed as a percentage
of the total tumor volume. P-values are included for
comparison between non-binned and binned image results
Average Dose Comparison - Non-Binned vs Binned
Control (%) 10mg/kg (%) 40mg/kg (%)
No Bins 0.7754
0.0686
0.0502
Binned 0.6417
0.0324
0.0189
P
0.7940
0.0234
0.0839

120mg/kg (%)
0.2199
0.1146
0.0653

Table 3.5: Associated p-values of ALDH1/DLL1 dose response
relationships for non-binned and binned images results
Dose Response Comparison - Non-Binned and Binned
Ctrl-LD Ctrl-MD Ctrl-HD LD-MD LD-HD MD-HD
No Bins 0.1465 0.1465 0.2232 0.2255 0.0435 0.0266
Binned 0.1611 0.1611 0.2074 0.2078 0.0383 0.0319

ALDH1/DLL1 overlap expressed in terms of total ALDH1-positive and DLL1positive expression regions are displayed in Figure 3.9 and 3.10. Of the total ALDH1positive populations identified, regions of overlap with DLL1-positive populations
accounted for 19.101%±15.313, 4.658%±2.013, 4.891%±1.975, and 12.598%±0.577 in
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% ALDH1 in ALDH1/DLL1 Overlap, Non-Binned vs
2x Binning
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Figure 3.9: ALDH1/DLL1 dose response to DC101, expressed in terms
of % of total ALDH1-positive regions

controls, LD, MD, and HD tumor groups in the non-binned image sets. In the binned
images, overlap accounted for 18.704%±16.943, 2.800%±0.992, 2.767%±1.309, and
9.520%±0.570 in controls, LD, MD, and HD tumor groups. Statistically significant (p <
0.05) differences were observed between LD and HD tumor groups and MD and HD
tumor groups for both non-binned and binned image sets.
Of the total DLL1-positive populations identified, regions of overlap with ALDH1positive populations account for 5.112%±2.447, 3.249%±0.698, 2.934%±1.602, and
1.774%±0.252 of controls, LD, MD, and HD tumor groups, respectively, in non-binned
image sets. For the binned images, overlap accounts for 4.115%±1.863, 1.951%±0.074,
1.684%±0.996, and 1.018%±0.216 of controls, LD, MD, and HD tumor groups,
respectively. Non-trivial (p < 0.10) differences were observed between control and HD
tumor groups and LD and HD tumor groups in the non-binned image sets; in the binned
image sets, these same differences became more significant (p < 0.05).
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% DLL1 in ALDH1/DLL1 Overlaps, Non-Binned vs
2x Binning
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Figure 3.10: ALDH1/DLL1 dose response to DC101, expressed in
terms of % of total DLL1-positive regions

Overlapping EpCAM/DLL1 expression response to DC101 dose from both nonbinned and binned images are displayed in Figure 3.11 and Tables 3.6 and 3.7 Average
overlap for controls, LD, MD, and HD tumor groups was observed to be 0.68%±0.660,
0.067%±0.038, 0.070%±0.049, and 0.591%±0.076, respectively, for the non-binned
image sets. For the binned image sets, average overlap was found to be 0.550%±0.567,
0.033%±0.023, 0.040%±0.035, and 0.499%±0.074, respectively. Statistically significant
(p < 0.05) difference were observed between the LD and HD groups and MD and HD
groups for both binned and non-binned images. No statistically significant differences
were observed between non-binned and binned tumor groups.
EpCAM/DLL1 overlap expressed in terms of total EpCAM-positive and DLL1positive expression regions are displayed in Figure 3.12 and 3.13. Of the total EpCAMpositive populations identified, regions of overlap with DLL1-positive populations
account for 18.947%±11.565, 3.572%±1.372, 5.679%±2.825, and 29.317%±8.523 in
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Dose Response of EpCAM/DLL1to DC101,
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Figure 3.11: EpCAM/DLL1 dose response to DC101 for nonbinned and binned images
Table 3.6: Average EpCAM/DLL1 expression for non-binned
and binned image results, expressed as a percentage of the
total tumor volume. P-values are included for comparison
between non-binned and binned image results
Average Dose Comparison - Non-Binned vs Binned
Control (%) 10mg/kg (%) 40mg/kg (%)
No Bins 0.6801
0.0674
0.0703
Binned 0.5499
0.0325
0.0397
p
0.7750
0.2548
0.4337

120mg/kg (%)
0.5911
0.4991
0.2079

Table 3.7: Associated p-values of EpCAM/DLL1 dose response
relationships for non-binned and binned image results
Dose Response Comparison - Non-Binned and Binned
Ctrl-LD Ctrl-MD Ctrl-HD LD-MD LD-HD MD-HD
No Bins 0.1601 0.1601 0.8061 0.9405 0.0020 0.0012
Binned 0.1654 0.1654 0.8703 0.7845 0.0049 0.0028

controls, LD, MD, and HD tumor groups, respectively, in the non-binned image sets. For
the binned image sets, overlap accounted for 19.457%±13.680, 2.083%±0.871,
4.123%±2.612, and 27.966%±2.303. Statistically significant (p < 0.05) differences were
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observed between LD and HD tumor groups and MD and HD tumor groups for both nonbinned and binned image sets. Non-trivial (p < 0.10) differences were also observed
between controls and LD tumor groups and controls and MD tumor groups for both nonbinned and binned image sets. No significant (p < 0.05) differences were observed
between binned and non-binned image sets of the same tumor groups.

% EpCAM in EpCAM/DLL1 Overlap, Non-Binning
vs 2x Binning
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Figure 3.12: EpCAM/DLL1 dose response to DC101, expressed in
terms of % of total EpCAM-positive regions
Of the total DLL1-positive populations identified, overlap with EpCAMpositive populations accounted for 5.321%±6.280, 2.793%±1.067, 2.421%±0.797, and
4.279%±1.368 in controls, LD, MD, and HD tumor groups, respectively, from nonbinned image sets. For the binned image sets, overlap accounted for 4.605%±6.251,
1.636%±0.815, 1.435%±0.775, and 4.096%±1.165 in controls, LD, MD, and HD tumor
groups, respectively. Statistically significant (p < 0.05) differences were observed
between LD and HD tumor groups and MD and HD tumor groups for the binned image
sets. No statistically significant (p < 0.05) differences were observed between binned and
non-binned tumor groups.
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Figure 3.13: EpCAM/DLL1 dose response to DC101, expressed in
terms of % of total DLL1-positive regions
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CHAPTER 4. CONCLUSION, DISCUSSIONS, AND FUTURE AIMS

4.1

Technique Validation

Utilizing our in-house Matlab and IDL scripts, our threshold-based quantification
technique estimated that ALDH1-positive pixels accounted for an average of 3.61%±1.39
of the SUM149 control tumor volumes. These findings correlate strongly with those
determined by Charafe-Jauffret et al12, who used the fluorescence-based ALDEFLOUR
assay to arrive at a similar conclusion (values range between 3.54% ± 1.73 and 5.49% ±
3.36 for the same cell type). Our agreement with independently-determined data obtained
through alternative means lends credence to the validity of our approach. The nearly fivefold abundance of DLL1 expression in control tumors compared to ALDH1 expression
suggests that the threshold value chosen for DLL1 may need to be modified, however this
cannot yet be verified due to lack of existing quantification data for both EpCAM and
DLL1 in the SUM149 breast cancer cell line in the literature. For this reason, future uses
of this technique should involve previously-quantified biomarkers for further validation
purposes.
Significant variations were observed in the control populations for both EpCAM
and DLL1, with ALDH1 variations proving to be consistent with those values previouslyreported. This may be less due to the technique and more so to the underpowered nature
of our study; only four mouse tumors were used to characterize the control populations,
which may have been insufficient to adequately cover the full range of expression values.
Analysis of the average tumor values (Table 4.1), however, reveals two outlying data
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points that greatly alter the total average: Mouse tumor 1 in the EpCAM group is nearly a
full order of magnitude larger than the other tumors in its group, and Mouse tumor 2 in
Table 4.1: Biomarker expression, by sample,
expressed as a % of total tumor volume
ALDH1 (%) EpCAM (%) DLL1 (%)
M1
3.4085
6.9104
10.0106
M2
1.2495
0.4941
0.8797
M3
1.7392
0.6350
26.1661
M4
3.5092
1.0547
23.6094
Average
2.4766
2.2735
15.1665
Std Dev
1.1524
3.1004
11.8739

the DLL1 group is two orders of magnitude smaller than the other tumors in its group.
Upon closer inspection, the Mouse 2 control tumor for DLL1 appeared to express almost
no DLL1 (Figure 4.1.1), either due to an error in the staining process or to abnormally
low expression of DLL1. The Mouse 1 control tumor did not appear to have anything
wrong with its staining after closer inspection (Figure 4.1), suggesting that the sample
size may have been too small to adequately cover the range of values for EpCAM
expression. Removing these points improved the deviations, changing the average
EpCAM and DLL1 expressions to 1.655 %±0.500 and 23.919%±9.888, respectively,
however the new averages were not found to vary from the original values by a
statistically significant difference.
The co-registration component adds an additional source of uncertainty, as minute
depth-based differences between tissue slices can hinder precise alignment of associated
images, which in turn can lead to false-positive and false-negative results during the
counting phase. Individual biomarker quantification (Aim 2) should not have been
affected by this step, as no inter-comparison between co-registered images was needed to
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A

B

Figure 4.1: Visual inspection of DLL1 (A) and EpCAM
(B) outliers reveals unusually low levels of DLL1
expression, but relatively normal EpCAM expression
acquire dose trends for individual biomarkers, however the accuracy of overlapping
biomarker quantification depends significantly on the precision of the co-registration
process. For this reason, binning was employed at the threshold step to overcome these
inaccuracies in the absence of a more direct measure of co-registration fidelity: By
reducing spatial resolution by a factor of 2, pixel values positive for a given biomarker
could be matched based on close proximity instead of direct pixel-to-pixel overlay.
Average results from binned image sets were consistently lower than their nonbinned counterparts and yielded statistically different results for three of the twelve
groups (controls, LD, MD, and HD groups for ALDH1, EpCAM, and DLL1), with nontrivial (p < 0.10) differences observed in another two groups. These results are
inconsistent with our expectations: In theory, the binning should have at the very least
kept the values equal, if not led to an increase in the number of recorded overlaps. After a
detailed re-evaluation of the overlap quantification script, it was determined that the code
may have been incrementally increasing the total tissue volume, which lead to decreased
overlap values in most cases. The script was subsequently re-worked and the results for
1x1, 2x2, 3x3, 4x4, 6x6, and 8x8 pixel bins were calculated for a single ALDH1/EpCAM
example set (Figure 4.2) to demonstrate successful rectification of the problem and the
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gradual increase in overlap that one would expect if the co-registration code were not
adequately aligning the two images.

Effects of Binning on ALDH1/EpCAM Overlap
Average % of Total Tissue Volume
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Figure 4.2: Binning effects for ALDH1/EpCAM overlap regions for a
single set of images demonstrates that there may be some error in the coregistation process
The gradual increase does suggest that co-registration errors exist, however the
fact that the trend does not plateau for the larger bins suggests that either the error in coregistration is significantly larger than our image resolution or that the larger bins are
including a significant number of false-positives. In either case, further investigation of
the co-registration process and its associated errors will be warranted in order to provide
certainty to any statements regarding overlapping pixel regions.

4.2

Dose Response

Perfusion imaging (Fig 4.3 and 4.4) results demonstrate that 40mg/kg doses,
corresponding to the MD tumor group, increased oxygen perfusion in the SUM149
tumors and decreased mean transit time compared to control values. This suggests that
DC101 doses of around 40mg/kg are having the desired normalization effect on tumor
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vasculature, allowing for greater blood flow through the tumor. Additionally, high
DC101 doses (120mg/kg) are shown to decrease perfusion and increase mean transit time
when compared to control values, demonstrating previous conclusions that high
concentrations of angiogenic inhibitor can disrupt tumor vasculature such that hypoxic
conditions within the tumor volume are worsened. These results will allow the dose
response of the target biomarkers to be discussed in the context of tissue oxygenation and
perfusion.
Our method demonstrates a gradual decrease in ALDH1 expression with increasing
DC101 dose, which begins to rise again after a certain dose point. The difference was
strongest for the 40mg/kg dose cohort, which showed a statistically significant 71%
decrease in expression compared to the control tumor group. ALDH1 expression then
nearly doubled between the 40mg/kg and 120mg/kg dose cohorts. These results are in
line with our predictions that a low-dose regimen will increase tumor oxygenation (an
observation further corroborated by our perfusion imaging data) and decrease processes
associated with hypoxia-induced CSC proliferation. EpCAM expression exhibited a
similar dose response pattern to ALDH1, however significant variation within all but the
120mg/kg dose category precluded any statistically significant patterns from emerging.
Removal of the aforementioned extraneous data point (control mouse 1) improves the
variation of the control group and brings the average EpCAM expression of the control
group below that of the 10mg/kg (LD) dose group (Figure 4.5). These data suggest that
EpCAM expression occurs independent of DC101 dose for the concentrations under
investigation and as such may not be recommended as a biomarker for future studies of
this kind.
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Figure 4.3: Changes in tumor perfusion and
fractional plasma volume are shown to be dose
dependent.

10 mg/kg

40 mg/kg

120 mg/kg

DC101 Dose

Figure 4.4: Mean transit time was
determined as a function of DC101 dose
based on data in Figure 4.2.1. Data are
trending towards greater efficiency in the
40mg/kg range, though not statistically
significant.

DLL1 expression decreased with both 10mg/kg (LD) and 40mg/kg (MD) doses of
DC101 by relatively similar amounts, compared to the control group, then increased
dramatically back to expression levels near that of the control group at 120mg/kg.
Removal of the aforementioned extraneous data point (control mouse 2) improves the
deviation in the control group and points to a potentially significant decrease in DLL1
expression between the control tumor group and the LD/MD tumor groups (Figure 4.6).
These data suggest that DLL1 activity can be decreased through low-level administration
of DC101 and the associated improvement of hypoxic conditions within the tumor
volume. As dose increases and tumor vasculature is cut off, DLL1 expression increases
significantly compared to the LD/MD tumor groups; increased severity of hypoxic
conditions appears to increase DLL1 expression in the tumor volume, in accordance with
expectations.
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Figure 4.5: Dose Response of EpCAM to DC101, excluding the mouse
1 data point. Results expressed as the average % of total tumor tissue
volume
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Figure 4.6: Dose Response of DLL1 to DC101, excluding the mouse 1
data point. Results expressed as the average % of total tumor tissue volume

4.3 Biomarker Overlap
Regions of overlap between ALDH1 and EpCAM were found to consistently
account for only a small fraction of both the total ALDH1-positive (~2-6%) and EpCAM-

35
positive (~2-7%) populations, in both binned and non-binned cases, for all dose
concentrations. Though we previously demonstrated a lack of dose response by EpCAM
to DC101, the relative lack of change to overlapping regions with dose suggests that
those regions positive for both biomarkers are being affected in equal quantity. As we
have previously demonstrated that ALDH1 expression does decrease with DC101 dose,
EpCAM expression would have to also decrease in order for the amount of overlap to
remain as constant as it is. This suggests that with a larger sample size, it may be possible
to reduce the variations observed in Figure 3.2.2 and show that the observed expression
trend does in fact mirror that of ALDH1. However, these inconsistencies may also be
indicative of errors in the co-registration process.
ALDH1 was found to overlap much more significantly with DLL1-positive
populations in the control group; nearly 20% of all ALDH1-positive pixels also tested
positive for DLL1 expression, in both non-binned and binned cases. These regions of
overlap decreased dramatically with the addition of DC101, down to between 4-5% (2-3%
in binned image sets) however large variations in expression values preclude any
statistical significance (p < 0.05) between these groups. This suggests the possibility that
if ALDH1 expression is being scaled back due to increased perfusion, then it is
happening in regions that are also positive for DLL1 expression. At high doses, overlap
was found to increase significantly (p < 0.05) from both LD and MD tumor group levels.
These results agree with our previous assessment that high DC101 doses caused
increased ALDH1 activity and that increases in ALDH1 are occurring in regions that are
also expressing DLL1.
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DLL1, conversely, exhibited a constant decrease in overlap with increasing dose,
ranging from ~5% (4% in binned image sets) in the control tumors down to ~ 2% (1% in
binned images) in the high-dose tumors. However, our previously-stated results
demonstrate that both DLL1 and ALDH1 expression significantly increases in the HD
tumor group with respect to the MD tumor groups. These findings suggest that while both
ALDH1 and DLL1 expression vary with DC101 dose, variations in DLL1 expression are
occurring independently of ALDH1.
The relationship between EpCAM and DLL1 with respect to overlap is similar to
that observed between DLL1 and ALDH1: Overlap between EpCAM-positive and
DLL1-positive regions account for nearly 20% of EpCAM-positive populations, however
these same regions only account for ~5% of DLL1-positive populations; LD and MD
groups see a decrease in overlap down to 4-5% of total EpCAM expression, which is
statistically indistinguishable from the observed 2-3% of total DLL1 expression due to
deviations in the average; in the HD group, overlap again increases to account for nearly
30% of overall EpCAM expression, while only accounting for a paltry 4% of overall
DLL1 expression. Again, as we have established that DLL1 dramatically increases in the
HD tumor group with respect to the MD group (Figure 3.2.3), this suggests that DLL1
expression is varying independently of EpCAM expression.
4.4

Conclusions and Future Direction

Using an in-house imaging threshold technique, we were able to demonstrate a
dose response relationship between ALDH1 and the VEGFR inhibitor, DC101.
Additionally we were able to show that DLL1 expression may also share a dose response
relationship with DC101. Variations in EpCAM measurements were too significant to
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demonstrate a dose response to DC101. Overlapping studies, though complicated by
binning issues, showed that a potential relationship may exist between EpCAM and
ALDH1 expression, and that ALDH1 and EpCAM expression may be closely correlated
with DLL1 expression. ALDH1 quantification was used to partially validate our
technique, though future studies should include more robust validation measures.
Through a combination of biomarker expression and perfusion imaging data, we
were able to show that normalization of tumor vasculature is possible and likely occurs
around DC101 dose concentrations of 40mg/kg, alleviating hypoxic conditions within the
tumors and decreasing the hallmarks of CSC populations. Accurately defining this “dose
window” will be the key to the clinical applicability of this research; the data and
methods covered herein represent the foundation of studies intended to identify and
control CSC populations through AAT, thereby improving clinical outcomes for cancer
patients.
In addition to further validation of this technique, future aims will attempt to
incorporate Principle Component Analysis into the imaging procedure. Unlike the
thresholds used in this experiment, which separate positive and negative expression
values based on a single color channel, PCA techniques use a color deconvolution
algorithm to decouple the contribution of each channel to a given stain20. Finally,
attempts will be made to co-register IHC slides with DCE-CT and PCT-S images in order
to identify an imaging parameter that varies with changes in CSC biomarker expression.
If successful, future cancer therapy treatments will be able to use existing imaging
modalities to monitor proliferation and migration of CSC populations from and within the
tumor site, potentially allowing greater therapeutic control over metastatic growth.
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